Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 2, 2010, Pages 186-192

  Liao, Zhiyong ^a   Lutz, Jacqueline ^a   Nevalainen, Marja T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Prostate cancer; Stat5a b; Therapy development

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PEPTIDE DERIVATIVE; PROLACTIN; PROLACTIN RECEPTOR ANTAGONIST; STAT5A PROTEIN; STAT5A PROTEIN INHIBITOR; STAT5B PROTEIN; STAT5B PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL VIABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE TARGETING; HUMAN; METASTASIS; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 73749083118     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.11.001     Document Type: Short Survey

References (113)

1. Ahonen T.J., Harkonen P.L., Laine J., Rui H., Martikainen P.M., and Nevalainen M.T. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140 (1999) 5412-5421
2. Ahonen T.J., Harkonen P.L., Rui H., and Nevalainen M.T. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143 (2002) 228-238
3. Ahonen T.J., Xie J., LeBaron M.J., Zhu J., Nurmi M., Alanen K., et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278 (2003) 27287-27292
4. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22 (2004) 503-529
5. Aoki N., and Matsuda T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 275 (2000) 39718-39726
6. Aoki N., and Matsuda T. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 16 (2002) 58-69
7. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
8. Becker S., Groner B., and Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394 (1998) 145-151
9. Chatterjee-Kishore M., Wright K.L., Ting J.P., and Stark G.R. How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J 19 (2000) 4111-4122
10. Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell Jr. J.E., and Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93 (1998) 827-839
11. Chen Y., Wen R., Yang S., Schuman J., Zhang E.E., Yi T., et al. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 278 (2003) 16520-16527
12. Choi J.Y., Li W.L., Kouri R.E., Yu J., Kao F.T., and Ruano G. Assignment of the acute phase response factor (APRF) gene to 17q21 by microdissection clone sequencing and fluorescence in situ hybridization of a P1 clone. Genomics 37 (1996) 264-265
13. Chughtai N., Schimchowitsch S., Lebrun J.J., and Ali S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem 277 (2002) 31107-31114
14. Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22 (2003) 1247-1252
15. Croker B.A., Kiu H., and Nicholson S.E. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19 (2008) 414-422
16. Dagvadorj A., Collins S., Jomain J.B., Abdulghani J., Karras J., Zellweger T., et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 148 (2007) 3089-3101
17. Dagvadorj A., Kirken R.A., Leiby B., Karras J., and Nevalainen M.T. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 14 (2008) 1317-1324
18. Darnell Jr. J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
19. de Groot R.P., Raaijmakers J.A., Lammers J.W., Jove R., and Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94 (1999) 1108-1112
20. Decker T., and Kovarik P. Serine phosphorylation of STATs. Oncogene 19 (2000) 2628-2637
21. Decker T., Lew D.J., Mirkovitch J., and Darnell Jr. J.E. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO J 10 (1991) 927-932
22. Ehret G.B., Reichenbach P., Schindler U., Horvath C.M., Fritz S., Nabholz M., et al. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276 (2001) 6675-6688
23. Evans M.K., Yu C.R., Lohani A., Mahdi R.M., Liu X., Trzeciak A.R., et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 26 (2007) 1941-1948
24. Foxwell B.M., Beadling C., Guschin D., Kerr I., and Cantrell D. Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells. Eur J Immunol 25 (1995) 3041-3046
25. Gewinner C., Hart G., Zachara N., Cole R., Beisenherz-Huss C., and Groner B. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279 (2004) 3563-3572
26. Ghoreschi K., Laurence A., and O'Shea J.J. Janus kinases in immune cell signaling. Immunol Rev 228 (2009) 273-287
27. Gillanders E.M., Xu J., Chang B.L., Lange E.M., Wiklund F., Bailey-Wilson J.E., et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 96 (2004) 1240-1247
28. Gouilleux F., Wakao H., Mundt M., and Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13 (1994) 4361-4369
29. Gouilleux F., Pallard C., Dusanter-Fourt I., Wakao H., Haldosen L.A., Norstedt G., et al. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J 14 (1995) 2005-2013
30. Goureau A., Garrigues A., Tosser-Klopp G., Lahbib-Mansais Y., Chardon P., and Yerle M. Conserved synteny and gene order difference between human chromosome 12 and pig chromosome 5. Cytogenet Cell Genet 94 (2001) 49-54
31. Gozgit J.M., Bebernitz G., Patil P., Ye M., Parmentier J., Wu J., et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 283 (2008) 32334-32343
32. Gross M., Liu B., Tan J., French F.S., Carey M., and Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20 (2001) 3880-3887
33. Guh J.Y., Huang J.S., Chen H.C., Hung W.C., Lai Y.H., and Chuang L.Y. Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am J Kidney Dis 38 (2001) 1096-1104
34. Haddad B., Pabon-Pena C.R., Young H., and Sun W.H. Assignment1 of STAT1 to human chromosome 2q32 by FISH and radiation hybrids. Cytogenet Cell Genet 83 (1998) 58-59
35. Halmos G., Schally A.V., Czompoly T., Krupa M., Varga J.L., and Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87 (2002) 4707-4714
36. Hennighausen L., and Robinson G.W. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 22 (2008) 711-721
37. Horvath C.M., Wen Z., and Darnell Jr. J.E. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9 (1995) 984-994
38. Hou J., Schindler U., Henzel W.J., Wong S.C., and McKnight S.L. Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 2 (1995) 321-329
39. Huang C.Y., Beliakoff J., Li X., Lee J., Sharma M., Lim B., et al. hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes. Mol Endocrinol 19 (2005) 2915-2929
40. Isaacs J.T. New strategies for the medical treatment of prostate cancer. BJU Int 96 Suppl. 2 (2005) 35-40
41. Isaacs J.T., and Isaacs W.B. Androgen receptor outwits prostate cancer drugs. Nat Med 10 (2004) 26-27
42. Iyer J., and Reich N.C. Constitutive nuclear import of latent and activated STAT5a by its coiled coil domain. FASEB J 22 (2008) 391-400
43. John S., Vinkemeier U., Soldaini E., Darnell Jr. J.E., and Leonard W.J. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 19 (1999) 1910-1918
44. Junicho A., Matsuda T., Yamamoto T., Kishi H., Korkmaz K., Saatcioglu F., et al. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 278 (2000) 9-13
45. Kawashima T., Bao Y.C., Minoshima Y., Nomura Y., Hatori T., Hori T., et al. A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell Biol 29 (2009) 1796-1813
46. Kazansky A.V., Spencer D.M., and Greenberg N.M. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 63 (2003) 8757-8762
47. Kindblom J., Dillner K., Ling C., Tornell J., and Wennbo H. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53 (2002) 24-33
48. Kindblom J., Dillner K., Sahlin L., Robertson F., Ormandy C., Tornell J., et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144 (2003) 2269-2278
49. Leek J.P., Hamlin P.J., Bell S.M., and Lench N.J. Assignment of the STAT6 gene (STAT6) to human chromosome band 12q13 by in situ hybridization. Cytogenet Cell Genet 79 (1997) 208-209
50. Letsch M., Schally A.V., Busto R., Bajo A.M., and Varga J.L. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 100 (2003) 1250-1255
51. Li P., Yu X., Ge K., Melamed J., Roeder R.G., and Wang Z. Heterogenous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161 (2002) 1467-1474
52. Li H., Ahonen T.J., Alanen K., Xie J., LeBaron M.J., Pretlow T.G., et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64 (2004) 4774-4782
53. Li H., Zhang Y., Glass A., Zellweger T., Gehan E., Bubendorf L., et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11 (2005) 5863-5868
54. Lin J.X., Mietz J., Modi W.S., John S., and Leonard W.J. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 271 (1996) 10738-10744
55. Linja M.J., Porkka K.P., Kang Z., Savinainen K.J., Janne O.A., Tammela T.L., et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10 (2004) 1032-1040
56. Litterst C.M., Kliem S., Marilley D., and Pfitzner E. NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J Biol Chem 278 (2003) 45340-45351
57. Liu X., Robinson G.W., Gouilleux F., Groner B., and Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 92 (1995) 8831-8835
58. Liu J.X., Mietz J., Modi W.S., John S., and Leonard W.J. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 271 (1996) 10738-10744
59. Llovera M., Pichard C., Bernichtein S., Jeay S., Touraine P., Kelly P.A., et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19 (2000) 4695-4705
60. Magne S., Caron S., Charon M., Rouyez M.C., and Dusanter-Fourt I. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol Cell Biol 23 (2003) 8934-8945
61. Maurer A.B., Wichmann C., Gross A., Kunkel H., Heinzel T., Ruthardt M., et al. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 99 (2002) 2647-2652
62. Meyer W.K., Reichenbach P., Schindler U., Soldaini E., and Nabholz M. Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription. J Biol Chem 272 (1997) 31821-31828
63. Mohler J.L., Gregory C.W., Ford OHr, Kim D., Weaver C.M., Petrusz P., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440-448
64. Mui A.L., Wakao H., Harada N., O'Farrell A.M., and Miyajima A. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol 57 (1995) 799-803
65. Mui A.L., Wakao H., O'Farrell A.M., Harada N., and Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14 (1995) 1166-1175
66. Nagel-Wolfrum K., Buerger C., Wittig I., Butz K., Hoppe-Seyler F., and Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2 (2004) 170-182
67. Nevalainen M.T., Valve E.M., Makela S.I., Blauer M., Tuohimaa P.J., and Harkonen P.L. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 129 (1991) 612-622
68. Nevalainen M.T., Valve E.M., Ingleton P.M., and Harkonen P.L. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 137 (1996) 3078-3088
69. Nevalainen M.T., Valve E.M., Ahonen T., Yagi A., Paranko J., and Harkonen P.L. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 11 (1997) 1297-1307
70. Nevalainen M.T., Valve E.M., Ingleton P.M., Nurmi M., Martikainen P.M., and Harkonen P.L. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 99 (1997) 618-627
71. Nevalainen M.T., Ahonen T.J., Yamashita H., Chandrashekar V., Bartke A., Grimley P.M., et al. Epithelial defect in prostates of Stat5a-null mice. Lab Invest 80 (2000) 993-1006
72. Pallard C., Gouilleux F., Benit L., Cocault L., Souyri M., Levy D., et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 14 (1995) 2847-2856
73. Palvimo J.J. PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem Soc Trans 35 (2007) 1405-1408
74. Paukku K., Yang J., and Silvennoinen O. Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcription 5. Mol Endocrinol 17 (2003) 1805-1814
75. Peng B., Sutherland K.D., Sum E.Y., Olayioye M., Wittlin S., Tang T.K., et al. CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity. Mol Endocrinol 16 (2002) 2019-2033
76. Penning T.M., and Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 1155 (2009) 33-42
77. In: Pestell R.G., and Nevalainen M.T. (Eds). Prostate cancer: signaling networks, genetics, and new treatment strategies (2008), Humana Press, Totowa, NJ, USA
78. Reich N.C., and Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 6 (2006) 602-612
79. Rycyzyn M.A., and Clevenger C.V. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99 (2002) 6790-6795
80. Schindler C., and Darnell Jr. J.E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64 (1995) 621-651
81. Schmidt D., and Muller S. PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60 (2003) 2561-2574
82. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6 (2000) 693-704
83. Sekimoto T., Nakajima K., Tachibana T., Hirano T., and Yoneda Y. Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4. J Biol Chem 271 (1996) 31017-31020
84. Sekimoto T., Imamoto N., Nakajima K., Hirano T., and Yoneda Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J 16 (1997) 7067-7077
85. Sharma M., Li X., Wang Y., Zarnegar M., Huang C.Y., Palvimo J.J., et al. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J 22 (2003) 6101-6114
86. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 16 (2006) 196-202
87. Soldaini E., John S., Moro S., Bollenbacher J., Schindler U., and Leonard W.J. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 20 (2000) 389-401
88. Stocklin E., Wissler M., Gouilleux F., and Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383 (1996) 726-728
89. Tan S.H., and Nevalainen M.T. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 15 (2008) 367-390
90. Tan S.H., Dagvadorj A., Shen F., Gu L., Liao Z., Abdulghani J., et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 68 (2008) 236-248
91. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653-4657
92. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276 (2001) 45443-45455
93. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3 (2004) 261-269
94. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 167 (2004) 197-201
95. Wakao H., Schmitt-Ney M., and Groner B. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kDa. J Biol Chem 267 (1992) 16365-16370
96. Wakao H., Gouilleux F., and Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13 (1994) 2182-2191
97. Wang L., and Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 11 (2004) 1319-1324
98. Wang Z., Prins G.S., Coschigano K.T., Kopchick J.J., Green J.E., Ray V.H., et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/Tantigen mouse. Endocrinology 146 (2005) 5188-5196
99. Wartmann M., Cella N., Hofer P., Groner B., Liu X., Hennighausen L., et al. Lactogenic hormone activation of Stat5 and transcription of the beta- casein gene in mammary epithelial cells is independent of p42 ERK2 mitogen-activated protein kinase activity. J Biol Chem 271 (1996) 31863-31868
100. Weiss-Messer E., Merom O., Adi A., Karry R., Bidosee M., Ber R., et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 220 (2004) 109-123
101. Wennbo H., Kindblom J., Isaksson O.G., and Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138 (1997) 4410-4415
102. Xu D., and Qu C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 13 (2008) 4925-4932
103. Xu X., Kreye E., Kuo C.B., and Walker A.M. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res 61 (2001) 6098-6104
104. Xu W., Yu F., Yan M., Lu L., Zou W., Sun L., et al. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells. J Cell Physiol 198 (2004) 188-196
105. Yamamoto K., Kobayashi H., Arai A., Miura O., Hirosawa S., and Miyasaka N. cDNA cloning, expression and chromosome mapping of the human STAT4 gene: both STAT4 and STAT1 genes are mapped to 2q32.2-->q32.3. Cytogenet Cell Genet 77 (1997) 207-210
106. Yamashita H., Xu J., Erwin R.A., Farrar W.L., Kirken R.A., and Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273 (1998) 30218-30224
107. Yamashita H., Nevalainen M.T., Xu J., LeBaron M.J., Wagner K.U., Erwin R.A., et al. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 183 (2001) 151-163
108. Yang E., Henriksen M.A., Schaefer O., Zakharova N., and Darnell Jr. J.E. Dissociation time from DNA determines transcriptional function in a STAT1 linker mutant. J Biol Chem 277 (2002) 13455-13462
109. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65 (2005) 939-947
110. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., and Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21 (2007) 1396-1408
111. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
112. Yuan X., and Balk S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27 (2009) 36-41
113. Zhu M., John S., Berg M., and Leonard W.J. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96 (1999) 121-130